Stay updated with breaking news from Induction Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing...
Catherine E. Lai, MD, MPH, discusses the current standard of care in the first-line treatment of patients with AML and which factors guide therapy selection.
The approval of oral, once-daily etrasimod 2 mg was based on positive data from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials.
A total of 136 patients were recruited in the Phase 2 trial sponsored and conducted by the French GERCOR Oncology Clinician Group, with the PRODIGE Intergroup and the supply of Tedopi® by OSE Immunotherapeutics.
High-efficacy therapies for multiple sclerosis have improved disease outcomes for many patients, but physicians are uncertain when to use them.